ReproCELL Incorporated (4978) Balance sheet

Market cap
¥12.2B
P/E ratio
-26.8x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
2014/032015/032016/032017/032018/032019/032020/032021/032022/032023/032024/032025/032026/03
Cash and cash equivalents -2,9183,4093,4133,5734,1134,5862,6012,6421,9152,9392,8232,604
Marketable securities, current -2,0002,0002,0002,0001,6006002,0002,0004,4653,6281,1183,904
Inventories-9510912168588445805874133127
Total current assets-5,3605,8615,9115,9806,2025,7315,2455,3797,1827,3994,8967,329
Property, plant and equipment, net-4862967217918817498101200242282
Marketable securities, non-current -631063475359305385432,5401,0051,3824,4041,914
Total non-current assets-2,2352,1071,9436181,2888228032,7161,1731,6534,7742,323
Total assets -7,5947,9687,8546,5987,4906,5536,0478,0958,3569,0539,6719,652
Short-term debt--53---------
Long-term debt, current ---32---80----
Total current liabilities-299456282261330407553827750678641617
Total non-current liabilities-21024420488888810317316345188
Total liabilities -509700486349419495656845781741686806
Retained earnings--1,471-3,517-4,429-6,601-7,203-8,219-9,032-750-515-54758-533
Stockholders' equity5,1957,0857,2687,3696,2487,0716,0585,3917,2517,5758,3128,9858,846
AI Chat